Management of respiratory syncytial virus infections

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 163-174

  Mills, John ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MIXTURE; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TOPICAL DRUG ADMINISTRATION; VIRUS INFECTION; VIRUS PNEUMONIA; VIRUS SHEDDING;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; RESPIRATORY SYNCYTIAL VIRUS; SYNCYTIAL VIRUS;

EID: 0029962119     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_17     Document Type: Conference Paper

References (59)

1. Hall CB, McCarthy CA. "Respiratory syncytial virus", Chapter 136 in Mandell GL, Bennett JE, Dolin R, Editors, Principles and Practice of Infectious Diseases, 4th Edition, Churchill Livingstone, New York 1995, p 1501-18.
2. Englund JA, Sullivan CJ, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Int Med 1988; 109:203-208.
3. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987-93.
4. Pohl C, Green M, Wald ER, et al. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis 1991;165:166-9.
5. Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature. Medicine 1989;68:269-81.
6. Whimbey E, Couch R, Englund J, et al. Respiratory syncytial virus (RSV) pneumonia among hospitalized adult patients with leukemia. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994. Abstract H84.
7. King JC, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 1993;12:733-9.
8. Chandwani S, Barkowsky W, Krasinski K, et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr 1990;117:251-4.
9. Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Children 1990;144:348.
10. Mathur U, Bentley DW, Hall CB. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann Int Med 1980;93:49-52.
11. Takimoto CH, Cram DI, Root RK. Respiratory syncytial virus infections on an adult medical ward. Arch Intern Med 1991;15:706-8.
12. Agius G, Dindinaud G, Biggar RJ, et al. An epidemic of respiratory syncytial virus in elderly people: Clinical and serological findings. J Med Virol 1990;30:117-27.
13. Guidry GG, Black-Payne CA, Payne DK, et al. Respiratory syncytial virus infection among intubated adults in a university medical intensive care unit. Chest 1991;100:1377-84.
14. Gilbert BE, Knight V. Overview of ribavirin, selenazole and derivatives. In Mills J, Corey L, editors, Antiviral Chemotherapy, New Directions for Clinical Application and Research. Elsevier, New York, 1986. p63-74.
15. Toltzis P. The mechanism of action of ribavirin. Ibid, 74-77.
16. McIntosh K. Chemotherapy of respiratory syncytial virus infections Ibid, 83-88.
17. Hayden FG. Update on antiviral chemotherapy of respiratory viral infections. In Mills J, Corey L, editors, Antiviral Chemotherapy, New Directions for Clinical Application and Research, vol 2. Elsevier, New York, 1989 p117-142.
18. Hayden FG. Antiviral agents (ribavirin). In Mandell GL, Bennett JE, Dolin R, Editors, Principles and Practice of Infectious Diseases, 4th Edition, Churchill Livingstone, New York 1995, p430-31.
19. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983;308:1443-7.
20. Hall CB, McBride JT, Gala CL, et al. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985;254:3047-3051.
21. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24.
22. Meert KL, Sarnaik AP, Gelmini MJ, et al. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double-blind, randomized trial. Crit Care Med 1994;22:566.
23. England JA, Piedra PA, Ahn YM, et al. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Ped 1994,125 635-41.
24. Wheeler JG, Wofford J, Turner MS, et al. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 1993;12:209-13.
25. Treanor JJ. Viral infections of the respiratory tract: prevention and treatment. Int J Antimicrob Agents 1994;4:1-22.
26. Chipps BE, Sullivan WF, Portnoy JM. Alpha-2A-interferon for treatment of bronchiolitis by respiratory syncytial virus. Pediatr Infect Dis J 1993;12:663-8.
27. Groothuis JR, Simoes EAF. Immunoprophylaxis and immunotherapy: role in the prevention and treatment of respiratory syncytial virus. Int J Antimicrob Agents 1993;2:97-104.
28. Rimensburger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of RSV infection in infants. Pediatr Inf Dis 1994;13:328-30.
29. Englund JA. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. [Review]. Pediatr Infect Dis J 1994;13:449-53.
30. García O, Martín M, Dopazo J, et al. Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol 1994;68:5448-5459.
31. Taylor G, Stott EJ, Bew M, et al. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunol 1984;52:137.
32. Walsh EE, Schlesinger JJ, Brandriss MW, et al. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984;43:756-758.
33. Chanock RM, Parrott RH, Connors M, et al. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatr 1992;90:137.
34. Hall CB. Prospects for a respiratory syncytial virus vaccine. [Review]. Science 1994;265:1393.
35. Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163:693-8.
36. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976;134:211.
37. Levin MJ. Treatment and prevention options for respiratory syncytial virus infections. J Pediatr 1994;124:522-527.
38. Piazza FM, Johnson SA, Ottolini MG, et al. Immunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 1992;166:1422-4.
39. Prince GA, Hemming VG, Horswood RL, et al. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1987;61:1851-1854.
40. Crowe JE, Murphy BR, Chanock RM, et al. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci 1994;91:1386-1390.
41. Weltzin R, Hsu SA, Mittlev ES, et al. Intranasal IgA against RSV protects against upper and lower respiratory tract infections in mice. Antimicrob Ag Chemother 1994;38:2785-91.
42. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Ag Chemother 1987;31:1882-1886.
43. Taylor G, Furze J, Tempest PR, et al. Humanised monoclonal antibody to respiratory syncytial virus. Lancet 1991;337:1411-1412.
44. Rimensberger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J 1994;13:328.
45. Siber GR, Leszcynski J, Pena CV, et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992;165:456-63.
46. Meissner HC, Fulton DR, Groothuis J, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Ag Chemother 1993;37:1655-8.
47. Groothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
48. Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. [Review]. Virus Res 1994;32:13.
49. Oien, NL, Brideau RJ, Thomsen DR, et al. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccine 1993;11:1040.
50. Crowe JEJ, Collins PL, London WT, et al. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993;11:1395-1404.
51. Crowe JJ, Bui PT, London WT, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis Vaccine 1994;12:691.
52. Hsu KH, Lubeck MD, Bhat BM, et al. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 1994;12:607.
53. Kakut TJ, Soike K, Brideau RT, et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993;167:553-61.
54. Hildreth SW, Baggs RR, Brownstein DG, et al. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization. Vaccine 1993;11:615.
55. Tristram DA, Welliver RC, Mohar CK, et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993;167:191-5.
56. Paradiso PR, Hildreth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Ped Infect Dis J 1994;13:792.
57. Tristram DA, Welliver RC, Hogerman DA, et al. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine 1994;12:551.
58. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993;168:1024-9.
59. Pringle CR, Filipiuk AH, Robinson BS, et al. Immunogenicity and pathogenicity of a triple temperature-sensitive modifed respiratory syncytial virus in adult volunteers. Vaccine 1993;11:473-8.